Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
In light of data shared in Lisbon, Portugal, HMTM indeed has prospective broad applicability for a wide demograhic contributing to equity of access to new treatment options. TauRx has initiated regulatory engagements in UK & US for intended product approval and subsequent commercialisation of HMTM.